(Q37676226)

21 August 2017

1 reference

title

Toxicity of sorafenib: clinical and molecular aspects (English)

1 reference

21 August 2017

6

Romain Coriat

1 reference

21 August 2017

Benoit Blanchet

1

1 reference

21 August 2017

Bertrand Billemont

2

1 reference

21 August 2017

Stéphane Barete

3

1 reference

21 August 2017

Hélène Garrigue

4

1 reference

21 August 2017

Laure Cabanes

5

1 reference

21 August 2017

Camille Francès

7

1 reference

21 August 2017

Bertrand Knebelmann

8

1 reference

21 August 2017

François Goldwasser

9

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Drug Safety

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

2

1 reference

21 August 2017

page(s)

275-287

1 reference

Targeting RAS signalling pathways in cancer therapy

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

BAY 43-9006 inhibition of oncogenic RET mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

BRAF is a therapeutic target in aggressive thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

BAY 43-9006: preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Dermatologic symptoms associated with the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Keratoacanthomas associated with sorafenib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Eruptive nevi associated with sorafenib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Management of hypertension in angiogenesis inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Angiogenic growth factors and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Vascular endothelial growth factor (VEGF)-A165-induced prostacyclin synthesis requires the activation of VEGF receptor-1 and -2 heterodimer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

The secretion of endothelin-1 by microvascular endothelial cells from human benign prostatic hyperplasia is inhibited by vascular endothelial growth factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Mechanisms of hypertension associated with BAY 43-9006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Sorafenib-induced eruptive melanocytic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Cutaneous side-effects of kinase inhibitors and blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Follicular thyroglobulin suppresses iodide uptake by suppressing expression of the sodium/iodide symporter gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Relationships between cell division, expression of growth factors and microcirculation in the thyroids of Tg-A2aR transgenic mice and patients with Graves' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Angiogenesis in the thyroid gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

Is BRAF the Achilles' Heel of Thyroid Cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740330903510608

10.1517/14740330903510608

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference